Scarica l'app Stockscreener
32.59
6.89%
-2.41
Pre-mercato:
32.70
0.11
+0.34%
Precedente Chiudi:
$35.00
Aprire:
$35
Volume 24 ore:
522.24K
Relative Volume:
1.26
Capitalizzazione di mercato:
$892.72M
Reddito:
$79.95M
Utile/perdita netta:
$-4.60M
Rapporto P/E:
-182.37
EPS:
-0.1787
Flusso di cassa netto:
$10.19M
1 W Prestazione:
+7.70%
1M Prestazione:
+38.03%
6M Prestazione:
+98.00%
1 anno Prestazione:
+60.94%
Intervallo 1D:
$32.52
$35.00
Intervallo di 1 settimana:
$29.87
$35.66
Portata 52W:
$13.09
$35.66
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Nome
Eton Pharmaceuticals Inc
Settore
Telefono
(847) 787-7361
Indirizzo
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
32.59 | 958.73M | 79.95M | -4.60M | 10.19M | -0.1787 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-23 | Reiterato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | B. Riley Securities | Buy |
| 2025-01-06 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2024-05-06 | Iniziato | Craig Hallum | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-01-04 | Reiterato | H.C. Wainwright | Buy |
| 2019-09-20 | Iniziato | B. Riley FBR | Buy |
| 2019-06-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie
ETON SEC FilingsEton Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy - Insider Monkey
Eton Pharmaceuticals Inc (ETON) Shares Fall 6.9% -- GF Value Says Still Overvalued - GuruFocus
ETON (Nasdaq) Rule 144 shows RSUs and Options grants dated 2024–2026 - Stock Titan
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
H.C. Wainwright reiterates Eton Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results By Investing.com - Investing.com Nigeria
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug - Investing.com
Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido - Moomoo
Eton (NASDAQ: ETON) licenses U.S. IMPAVIDO rights in rare disease push - Stock Titan
Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO®, First FDA-Approved Oral Therapy for Leishmaniasis - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals, Inc.Common Stock (NQ: ETON - The Chronicle-Journal
Price-Driven Insight from (ETON) for Rule-Based Strategy - Stock Traders Daily
H.C. Wainwright raises Eton Pharmaceuticals stock price target to $57 By Investing.com - Investing.com Canada
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2026 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals Q1 Non-GAAP EPS, Revenue Rise - Moomoo
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Eton projects revenue to exceed $120M in 2026 as it targets a 50% adjusted EBITDA margin by 2028 - MSN
Eton Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
MSN Money - MSN
Eton Pharmaceuticals, Inc. (ETON) misses Q1 earnings estimates - MSN
ETON: Record Q1 sales and new product launches drive raised 2026 revenue guidance above $120 million - TradingView
Eton Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Eton Pharmaceuticals Q1 2026 revenue beats, EPS misses - Investing.com
Eton Pharmaceuticals earnings missed by $0.14, revenue topped estimates - Investing.com
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates - Yahoo Finance
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call - Benzinga
ETON PHARMACEUTICALS ($ETON) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Eton Pharmaceuticals (ETON) swings to Q1 2026 profit as rare disease sales grow - Stock Titan
Surging sales turn Eton Pharmaceuticals (NASDAQ: ETON) profitable in Q1 2026 - Stock Titan
Earnings Flash (ETON) Eton Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.14 per Share, vs. FactSet Est of $0.14 - marketscreener.com
Earnings Flash (ETON) Eton Pharmaceuticals, Inc. Reports Q1 Revenue $24.3M, Vs. FactSet Est of $22.3M - Moomoo
Press Release: Eton Pharmaceuticals Reports First Quarter 2026 Financial Results - Moomoo
Does Eton Pharmaceuticals (ETON) have the potential to rally 49.25% as Wall Street analysts expect? - MSN
Eton Pharmaceuticals Q1 2026 earnings preview - MSN
Eton Pharmaceuticals raises 2026 revenue forecast after Q1 sales jump 73% and new product launches. - Pluang
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Eton Pharmaceuticals Inc Azioni (ETON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):